Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $41.50.

A number of research firms recently weighed in on OCS. Chardan Capital restated a “buy” rating and set a $51.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright increased their target price on Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Bank of America lowered their price target on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, November 13th.

Oculis Trading Up 5.8%

Shares of NASDAQ:OCS opened at $25.22 on Friday. The stock has a 50 day moving average of $20.36 and a 200 day moving average of $19.13. The company has a market cap of $1.32 billion, a PE ratio of -10.01 and a beta of 0.31. Oculis has a 12-month low of $14.00 and a 12-month high of $26.17. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.10. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. As a group, equities research analysts expect that Oculis will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Aberdeen Group plc increased its holdings in Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after acquiring an additional 493,827 shares during the last quarter. Syquant Capital Sas purchased a new position in shares of Oculis during the fourth quarter valued at about $3,849,000. Compagnie Lombard Odier SCmA grew its position in shares of Oculis by 10.6% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock valued at $2,143,000 after purchasing an additional 10,300 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.